Cardiac Involvement in Storage Disorders: Pathophysiology, Multimodality Diagnosis, and Emerging Disease-Modifying Therapies

Cardiac involvement is a major determinant of morbidity and mortality in storage disorders, including Fabry disease, Pompe disease, Danon disease, PRKAG2 syndrome, transthyretin and light-chain amyloidosis, the mucopolysaccharidoses, Gaucher disease, and Niemann-Pick disease. Because their cardiac phenotype mimics hypertensive heart disease, athlete's heart, and sarcomeric hypertrophic cardiomyopathy, these conditions are often recognised only after irreversible myocardial fibrosis has developed, when disease-specific therapy is least effective. This narrative review aims to summarise the pathophysiology, disease-specific phenotypes, multimodality imaging, molecular diagnosis, and current and emerging treatment of storage cardiomyopathies, framed around the clinical problem of unexplained left ventricular hypertrophy and restrictive physiology. Relevant literature was identified through PubMed/MEDLINE, Embase, Scopus, and Web of Science, supplemented by hand-searching of guidelines and consensus statements, with priority given to randomised trials, registries, and expert consensus. Although their upstream biology differs, storage cardiomyopathies converge on common pathways of substrate accumulation, lysosomal and mitochondrial dysfunction, fibrosis, and electrical instability. Native T1 and T2 mapping, extracellular volume quantification, late gadolinium enhancement, strain echocardiography, and bone scintigraphy now permit earlier and more specific diagnosis. Enzyme replacement therapy, pharmacological chaperones, transthyretin stabilisers, and RNA-targeted agents are most effective when started before fibrosis is established, whereas gene replacement and genome editing remain investigational. Early recognition through structured multimodality imaging and molecular diagnosis, combined with multidisciplinary care, is essential to ensure timely disease-specific therapy and improve long-term outcomes.

Authors

Publication Details

Journal
Journal of chemical health risks
Published
2026-11-13
Primary Topic
Lysosomal Storage Disorders Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cardiac Involvement in Storage Disorders: Pathophysiology, Multimodality Diagnosis, and Emerging Disease-Modifying Therapies

L. Jacqueline
Journal of chemical health risks
Lysosomal Storage Disorders Research
article

Cardiac Involvement in Storage Disorders: Pathophysiology, Multimodality Diagnosis, and Emerging Disease-Modifying Therapies

L. Jacqueline
article en

Abstract

Cardiac involvement is a major determinant of morbidity and mortality in storage disorders, including Fabry disease, Pompe disease, Danon disease, PRKAG2 syndrome, transthyretin and light-chain amyloidosis, the mucopolysaccharidoses, Gaucher disease, and Niemann-Pick disease. Because their cardiac phenotype mimics hypertensive heart disease, athlete's heart, and sarcomeric hypertrophic cardiomyopathy, these conditions are often recognised only after irreversible myocardial fibrosis has developed, when disease-specific therapy is least effective. This narrative review aims to summarise the pathophysiology, disease-specific phenotypes, multimodality imaging, molecular diagnosis, and current and emerging treatment of storage cardiomyopathies, framed around the clinical problem of unexplained left ventricular hypertrophy and restrictive physiology. Relevant literature was identified through PubMed/MEDLINE, Embase, Scopus, and Web of Science, supplemented by hand-searching of guidelines and consensus statements, with priority given to randomised trials, registries, and expert consensus. Although their upstream biology differs, storage cardiomyopathies converge on common pathways of substrate accumulation, lysosomal and mitochondrial dysfunction, fibrosis, and electrical instability. Native T1 and T2 mapping, extracellular volume quantification, late gadolinium enhancement, strain echocardiography, and bone scintigraphy now permit earlier and more specific diagnosis. Enzyme replacement therapy, pharmacological chaperones, transthyretin stabilisers, and RNA-targeted agents are most effective when started before fibrosis is established, whereas gene replacement and genome editing remain investigational. Early recognition through structured multimodality imaging and molecular diagnosis, combined with multidisciplinary care, is essential to ensure timely disease-specific therapy and improve long-term outcomes.

Journal of chemical health risks
Lysosomal Storage Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon